Morgan Stanley’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-20,310
| Closed | -$21K | – | 6955 |
|
|
2019
Q1 | $21K | Buy |
20,310
+14,446
| +246% | +$11.8K | ﹤0.01% | 6008 |
|
|
2018
Q4 | $4K | Sell |
5,864
-7,058
| -55% | -$10.6K | ﹤0.01% | 6361 |
|
|
2018
Q3 | $28K | Buy |
12,922
+590
| +5% | +$1.41K | ﹤0.01% | 6053 |
|
|
2018
Q2 | $29K | Buy |
12,332
+5,365
| +77% | +$15.6K | ﹤0.01% | 6062 |
|
|
2018
Q1 | $22K | Buy |
6,967
+850
| +14% | +$2.34K | ﹤0.01% | 6111 |
|
|
2017
Q4 | $25K | Sell |
6,117
-29,938
| -83% | -$130K | ﹤0.01% | 6024 |
|
|
2017
Q3 | $163K | Buy |
36,055
+7,476
| +26% | +$30.3K | ﹤0.01% | 5435 |
|
|
2017
Q2 | $95K | Sell |
28,579
-24,268
| -46% | -$101K | ﹤0.01% | 5657 |
|
|
2017
Q1 | $487K | Sell |
52,847
-56,096
| -51% | -$493K | ﹤0.01% | 4854 |
|
|
2016
Q4 | $840K | Buy |
108,943
+20,427
| +23% | +$188K | ﹤0.01% | 4599 |
|
|
2016
Q3 | $1.01M | Buy |
88,516
+63,302
| +251% | +$737K | ﹤0.01% | 4028 |
|
|
2016
Q2 | $311K | Buy |
25,214
+4,074
| +19% | +$49.4K | ﹤0.01% | 4710 |
|
|
2016
Q1 | $214K | Sell |
21,140
-129,122
| -86% | -$1.52M | ﹤0.01% | 4936 |
|
|
2015
Q4 | $3.39M | Buy |
150,262
+40,178
| +36% | +$823K | ﹤0.01% | 3041 |
|
|
2015
Q3 | $1.83M | Buy |
110,084
+6,139
| +6% | +$123K | ﹤0.01% | 3597 |
|
|
2015
Q2 | $2.34M | Buy |
103,945
+1,262
| +1% | +$31.1K | ﹤0.01% | 3484 |
|
|
2015
Q1 | $2.65M | Buy |
102,683
+8,874
| +9% | +$225K | ﹤0.01% | 3324 |
|
|
2014
Q4 | $2.04M | Buy |
93,809
+21,334
| +29% | +$437K | ﹤0.01% | 3545 |
|
|
2014
Q3 | $1.37M | Buy |
72,475
+67,514
| +1,361% | +$1.36M | ﹤0.01% | 3761 |
|
|
2014
Q2 | $116K | Sell |
4,961
-34,761
| -88% | -$858K | ﹤0.01% | 5432 |
|
|
2014
Q1 | $1.34M | Buy |
39,722
+27,978
| +238% | +$943K | ﹤0.01% | 3756 |
|
|
2013
Q4 | $347K | Buy |
11,744
+1,503
| +15% | +$27.5K | ﹤0.01% | 4721 |
|
|
2013
Q3 | $157K | Buy |
+10,241
| New | +$190K | ﹤0.01% | 4975 |
|
Morgan Stanley's OMED Position: Q2 2019 in Review
Morgan Stanley sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2019, closing a stake of 20,310 shares — an estimated $21K sold.
Morgan Stanley first reported a position in OMED in Q3 2013 and held it in 23 quarters. The position peaked at $3.39M in Q4 2015. 0 funds tracked by Wall St. Rank hold OMED as of Q2 2019.
- Morgan Stanley reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
- Morgan Stanley sold 20,310 OncoMed Pharmaceuticals, Inc. shares in Q2 2019, an estimated $21K.
- Morgan Stanley first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and held it in 23 quarters.
- Morgan Stanley's OncoMed Pharmaceuticals, Inc. position peaked at $3.39M in Q4 2015.
- 0 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2019.
Based on Morgan Stanley's 13F filing for Q2 2019, filed 14 Aug 2019.